The Pediatric-Oncology Research Landscape is Changing. Are You Prepared?
Cancer is the leading cause of death by disease in the US for the pediatric population. While cure rates have risen overall, there is much to be done to improve the outcomes of many diagnoses, as well as late effects related to conventional treatments. The growing role of precision medicine in oncology research promises to finally transform pediatric cancer drug development and the therapies available to childhood cancer patients. In response, The Food & Drug Administration is enacting the Research to Accelerate Cures & Equity (RACE) for Children Act, which will require new drugs intended for adult cancer treatment to be studied in pediatric cancers when the molecular target of the drug is relevant to pediatric oncology.
In this white paper you will learn about:
• The history behind existing regulation regarding pediatric clinical studies
• The RACE Act's application to precision medicine
• The unique challenges that accompany pediatric studies and how to navigate them
• The importance of collaboration across industry for designing pediatric oncology studies
Offered Free by: PRA Health Sciences
See All Resources from: PRA Health Sciences